Literature DB >> 18052719

Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application.

Alfonso Quintás-Cardama1, Raymond K Yeh, Daniel Hollyman, Jolanta Stefanski, Clare Taylor, Yan Nikhamin, Gavin Imperato, Michel Sadelain, Isabelle Rivière, Renier J Brentjens.   

Abstract

The ability to genetically modify human T cells to target tumor antigens through retroviral gene transfer constitutes a potentially powerful approach to cancer immunotherapy. However, low transduction efficiencies may hamper the efficacy of such therapeutic strategies in the clinical setting. Most commonly, gammaretroviral gene transfer into T cells is conducted through spinoculation, that is, centrifugation of retroviral particles and T cells on RetroNectin-coated non-tissue culture vessels. Here we present data investigating the impact of temperature, speed, and frequency of spinoculation on T cell transduction efficiencies. We found that all three variables independently impacted gene transfer, with increasing temperature, speed, and frequency of spinoculation all enhancing the transduction of T cells. These improved conditions were additive, with the greatest proportion of transduced T cells being generated at the highest tested temperature and speed, after daily spinoculation for 2 to 3 days. Under these conditions, enhanced gene transfer was observed in T cells derived from healthy donors, using research-grade vector stocks. Whereas both RetroNectin and spinoculation were critical to optimal gene transduction, preloading of gammaretroviral particles before spinoculation did not enhance gene transfer. Significantly, application of these enhanced transduction conditions to T cells derived from previously treated patients with chronic lymphocytic leukemia allowed for adequate gene transfer under both small-scale and large-scale clinically applicable conditions using either preclinical or current Good Manufacturing Practice-grade gammaretroviral vector stocks.

Entities:  

Mesh:

Year:  2007        PMID: 18052719     DOI: 10.1089/hum.2007.088

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  15 in total

1.  Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.

Authors:  Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

2.  Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

Authors:  Alena A Chekmasova; Thapi D Rao; Yan Nikhamin; Kay J Park; Douglas A Levine; David R Spriggs; Renier J Brentjens
Journal:  Clin Cancer Res       Date:  2010-07-13       Impact factor: 12.531

3.  HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases.

Authors:  Steven C Katz; John Hardaway; Ethan Prince; Prajna Guha; Marissa Cunetta; Ashley Moody; Li Juan Wang; Vincent Armenio; N Joseph Espat; Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2019-06-03       Impact factor: 5.987

4.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Authors:  Kevin J Curran; Beatrijs A Seinstra; Yan Nikhamin; Raymond Yeh; Yelena Usachenko; Dayenne G van Leeuwen; Terence Purdon; Hollie J Pegram; Renier J Brentjens
Journal:  Mol Ther       Date:  2015-01-13       Impact factor: 11.454

5.  Quality cell therapy manufacturing by design.

Authors:  Yonatan Y Lipsitz; Nicholas E Timmins; Peter W Zandstra
Journal:  Nat Biotechnol       Date:  2016-04       Impact factor: 54.908

6.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.

Authors:  Steven C Katz; Rachel A Burga; Elise McCormack; Li Juan Wang; Wesley Mooring; Gary R Point; Pranay D Khare; Mitchell Thorn; Qiangzhong Ma; Brian F Stainken; Earle O Assanah; Robin Davies; N Joseph Espat; Richard P Junghans
Journal:  Clin Cancer Res       Date:  2015-04-07       Impact factor: 12.531

7.  IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Authors:  Mythili Koneru; Terence J Purdon; David Spriggs; Susmith Koneru; Renier J Brentjens
Journal:  Oncoimmunology       Date:  2015-01-23       Impact factor: 8.110

8.  Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Authors:  Eric L Smith; Mette Staehr; Reed Masakayan; Ishan J Tatake; Terence J Purdon; Xiuyan Wang; Pei Wang; Hong Liu; Yiyang Xu; Sarah C Garrett-Thomson; Steven C Almo; Isabelle Riviere; Cheng Liu; Renier J Brentjens
Journal:  Mol Ther       Date:  2018-03-28       Impact factor: 11.454

9.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

10.  Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase.

Authors:  Elmer B Santos; Raymond Yeh; James Lee; Yan Nikhamin; Blesida Punzalan; Blesserene Punzalan; Krista La Perle; Steven M Larson; Michel Sadelain; Renier J Brentjens
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.